JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study-Reference-Cited by-同舟云学术

JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study

Published:2022-10-26 Issue:12 Volume:78 Page:1981-1990
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Gouverneur Amandine^ORCID,Avouac Jérôme^ORCID,Prati Clément,Cracowski Jean-Luc^ORCID,Schaeverbeke Thierry,Pariente Antoine^ORCID,Truchetet Marie-Elise

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-022-03402-2.pdf

Reference38 articles.

1. European Medicines Agency (2021) Olumiant (baricitinib) - summary of product characteristics

2. US Food and Drug Administration (2018) Olumiant (baricitinib): highlights of prescribing information

3. European Medicines Agency (2021) Xeljanz (tofacitinib) - summary of product characteristics

4. US Food and Drug Administration (2020) Xeljanz (tofacitinib): highlights of prescribing information

5. Richez C, Truchetet M-E, Kostine M et al (2017) Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opin Pharmacother 18:1399–1407. https://doi.org/10.1080/14656566.2017.1359256

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study;International Immunopharmacology;2024-03

2. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry;Arthritis Research & Therapy;2023-09-19

3. Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis;Rheumatology and Therapy;2023-09-16

4. Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases;Joint Bone Spine;2023-09

5. Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism;International Journal of Molecular Sciences;2023-08-08